Intestinal FXR is activated in high-fat-fed mice and the use of intestinal FXR inhibitors could reduce ceramide production and control hypercholesterolemia, leading to new directions in the treatment of atherosclerosis (Wu et al., 2021). Here, NR1H4 is linked to atherosclerosis.